First Tracks Biotherapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
John A Orwin, a Director of First Tracks Biotherapeutics, Inc., reported multiple transactions in common stock on September 15, 2026.
NASDAQ
J. Anthony Ware, a Director of First Tracks Biotherapeutics, Inc., sold 39,265 shares of common stock on September 2, 2026 for $44.78 per share.
NASDAQ
Benjamin Stone, Chief Business Officer of First Tracks Biotherapeutics, Inc., received 60,492 shares of common stock on August 15, 2026.
NASDAQ
Paul F. Lizzul, Chief Medical Officer of First Tracks Biotherapeutics, Inc., received 60,492 shares of common stock on August 15, 2026.
NASDAQ
Daniel Faga, President, CEO and a Director of First Tracks Biotherapeutics, Inc., received 193,575 shares of common stock on August 15, 2026.
NASDAQ
Benjamin Stone, Chief Business Officer of First Tracks Biotherapeutics, Inc., received 60,492 shares of common stock on August 2, 2026.
NASDAQ
Paul F. Lizzul, Chief Medical Officer of First Tracks Biotherapeutics, Inc., received 60,492 shares of common stock on August 2, 2026.
NASDAQ
Daniel Faga, President, CEO and a Director of First Tracks Biotherapeutics, Inc., received 193,576 shares of common stock on August 2, 2026.